The treatment lasts around three hours, including observation.
It is not a vaccine and is not expected to cause permanent immunity.
Results showed that antibodies were higher than those who suffered severe cases of the virus.
Two studies will examine whether an antibody combination reduces the risk of developing COVID-19 and/or reduces the severity of the infection compared to a placebo.
Roche’s Elecsys Anti-SARS-CoV-2 test US Food and Drug Administration (FDA) emergency use administration in May.
Researchers called for a larger study of humoral immunity, saying that their small study emphasizes the need for further research.
The study, carried out in a joint effort by British and Guinean scientists, is the world's largest and most comprehensive one to date to examine survivors of the Ebola virus.
Bnei Brak serological survey shows at least 9% of city had corona
Lead scientist: ‘Asymptomatic patients may possibly contract disease a second time’
The IIBR updated Gantz that it is prepared to begin the human testing phase of trials on October 21 and is waiting for approval from the Health Ministry's Helinski Committee.